{"nct_id":"NCT04721977","title":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-05","start_date":"2021-04-08","start_date_type":"ACTUAL","primary_completion_date":"2023-07-17","primary_completion_date_type":"ACTUAL","completion_date":"2025-11-25","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["PFE"]}